Insights

High-Need Markets BC3 Technologies specializes in antihemorrhagic products for medical, military, and consumer sectors, indicating multiple potential sales channels including hospitals, EMS teams, law enforcement, and consumer safety retailers.

Proven SEAL Adoption The professional version of SEAL has been adopted by numerous police departments and EMS groups, signaling traction with first responders and potential expansions to additional jurisdictions and agencies seeking rapid hemorrhage control solutions.

Strategic Partnerships Partnership with First Aid Only for SEAL distribution highlights a ready-made, wide distribution network in safety and workplace first aid channels, enabling scale without building from scratch.

Funding & Growth With revenue in the low millions and a funding level of several million dollars, there is momentum to support scaling, field trials, and broader product deployment across public sector and commercial customers.

Small Team Advantage A compact team focused on technology and product development suggests agility for rapid iterations and targeted outreach to large corporate and government procurement teams, particularly in defense, EMS, and medical sectors.

BC3 Technologies Tech Stack

BC3 Technologies uses 8 technology products and services including gstatic.com, Open Graph, NSONE, and more. Explore BC3 Technologies's tech stack below.

  • gstatic.com
    Content Delivery Network
  • Open Graph
    Content Management System
  • NSONE
    Domain Name Services
  • Google Workspace
    Email
  • YouTube
    Video Players
  • Google Analytics
    Web Analytics
  • Apache HTTP Server
    Web Servers
  • Apache
    Web Servers

BC3 Technologies's Email Address Formats

BC3 Technologies uses at least 1 format(s):
BC3 Technologies Email FormatsExamplePercentage
First@bc3tech.comJohn@bc3tech.com
100%

Frequently Asked Questions

What is BC3 Technologies's official website and social media links?

Minus sign iconPlus sign icon
BC3 Technologies's official website is bc3tech.com and has social profiles on LinkedInCrunchbase.

How much revenue does BC3 Technologies generate?

Minus sign iconPlus sign icon
As of August 2026, BC3 Technologies's annual revenue is estimated to be $1M - $10M.

What is BC3 Technologies's SIC code NAICS code?

Minus sign iconPlus sign icon
BC3 Technologies's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BC3 Technologies have currently?

Minus sign iconPlus sign icon
As of August 2026, BC3 Technologies has approximately 8 employees across 1 continents, including North America. Key team members include Chief Strategy Officer (cso): K. C.President: W. G.. Explore BC3 Technologies's employee directory with LeadIQ.

What industry does BC3 Technologies belong to?

Minus sign iconPlus sign icon
BC3 Technologies operates in the Biotechnology Research industry.

What technology does BC3 Technologies use?

Minus sign iconPlus sign icon
BC3 Technologies's tech stack includes gstatic.comOpen GraphNSONEGoogle WorkspaceYouTubeGoogle AnalyticsApache HTTP ServerApache.

What is BC3 Technologies's email format?

Minus sign iconPlus sign icon
BC3 Technologies's email format typically follows the pattern of First@bc3tech.com. Find more BC3 Technologies email formats with LeadIQ.

How much funding has BC3 Technologies raised to date?

Minus sign iconPlus sign icon
As of August 2026, BC3 Technologies has raised $3.8M in funding. The last funding round occurred on Nov 26, 2025 for $150K.

When was BC3 Technologies founded?

Minus sign iconPlus sign icon
BC3 Technologies was founded in 2018.
BC3 Technologies logo

BC3 Technologies

Biotechnology ResearchMaryland, United States2-10 Employees

BC3 Technologies, based in Baltimore, Maryland, is a small biotechnology research firm focused on antihemorrhagic products for medical, military, and consumer markets. The company employs a proprietary chitosan-based aerosol that can be applied to wounds and supports rapid clotting, with performance and cost comparable to existing products. The technology is described as stable and versatile, aiming for a broad range of applications.

Its customers include healthcare providers, emergency responders, and other users seeking effective wound control. In September 2023, BC3 Technologies released a professional version of SEAL, its hemostatic wound spray, which has been adopted by police departments and EMS across the United States. In September 2024, the company announced a distribution partnership with First Aid Only to expand SEAL's reach.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
2-10

Section iconFunding & Financials

  • $3.8M

    BC3 Technologies has raised a total of $3.8M of funding over 3 rounds. Their latest funding round was raised on Nov 26, 2025 in the amount of $150Kas a series_unknown.

  • $1M - $10M

    BC3 Technologies's revenue is estimated to be in the range of $1M - $10M

Section iconFunding & Financials

  • $3.8M

    BC3 Technologies has raised a total of $3.8M of funding over 3 rounds. Their latest funding round was raised on Nov 26, 2025 in the amount of $150Kas a series_unknown.

  • $1M - $10M

    BC3 Technologies's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.